CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...
On December 9, 2019, the new CTS Laboratory Information System successfully implemented in Phoe...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...